Retina/Vitreous

Top Story

Anti-VEGF injections may cause anxiety, depression in patients

March 30, 2017

In an observational study, 56% of patients undergoing anti-VEGF injections reported experiencing anxiety related to the intravitreal treatment for wet age-related macular degeneration.

Three hundred patients with wet AMD receiving anti-VEGF treatment at Manchester Royal Eye Hospital, U.K., were included in the cross-sectional, mixed-methods study. A survey was administered to evaluate patient experience related to undergoing anti-VEGF treatment.

In the Journals

Artificial intelligence-based algorithm screens for diabetic retinopathy

March 29, 2017
A novel artificial intelligence-based algorithm proved effective as a tool to automate screening for diabetic retinopathy, according to a study. Deep learning methods…
In the Journals

Aflibercept for AMD largely maintains visual gains through 212 weeks

March 28, 2017
Vision gains achieved in the VIEW 1 trial were “largely maintained” at the conclusion of the VIEW 1 Extension Study, according to the study results. In the…
Grand Rounds at the New England Eye Center

Woman presents with spontaneous visual field loss

Ocular Surgery News U.S. Edition, April 10, 2017
James Constans, MD; Thomas R. Hedges III, MD
The New England Eye Center was consulted on a 61-year-old woman with a history of recently diagnosed left-sided greater than right-sided internal carotid artery…
Clinical Science

Change in Diabetic Panretinal Photocoagulation Incidence

Ophthalmic Surgery, Lasers and Imaging Retina, July 2012, Volume 43 Issue 4
Diabetic blindness occurs most often among working-age people. Panretinal photocoagulation (PRP) can prevent this…
More »
COPE

Diabetic Eye Disease: Screening Strategies and Imaging Devices - Number 1

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence…
More »
Featured
World Retina Congress

World Retina Congress

Video

Genentech completes enrollment in two phase 3 lampalizumab studies

February 2, 2017
More »
In the Journals

Anti-VEGF injections may cause anxiety, depression in patients

March 30, 2017
In an observational study, 56% of patients undergoing anti-VEGF injections reported experiencing anxiety related to the intravitreal treatment for…

In the Journals

Artificial intelligence-based algorithm screens for diabetic retinopathy

March 29, 2017
A novel artificial intelligence-based algorithm proved effective as a tool to automate screening for diabetic retinopathy, according to a study. …

In the Journals

Aflibercept for AMD largely maintains visual gains through 212 weeks

March 28, 2017
Vision gains achieved in the VIEW 1 trial were “largely maintained” at the conclusion of the VIEW 1 Extension Study, according to the…

Grand Rounds at the New England Eye Center

Woman presents with spontaneous visual field loss

Ocular Surgery News U.S. Edition, April 10, 2017
James Constans, MD; Thomas R. Hedges III, MD
The New England Eye Center was consulted on a 61-year-old woman with a history of recently diagnosed left-sided greater than right-sided internal…

In the Journals

Teleretinal diabetic retinopathy screening program decreases need for referrals

March 27, 2017
Screening rates were increased and both the need for referral and wait time for screening were reduced for patients who participated in a large-scale…

PUBLICATION EXCLUSIVE: Which DRCR.net protocol has had the biggest impact on your practice?

March 25, 2017
Click here to view the Cover Story for this Point/Counter.

ONL Therapeutics receives approximately $1 million grant from NEI

March 23, 2017
The National Eye Institute has awarded ONL Therapeutics a grant worth almost $1 million to continue developing its lead therapeutic candidate…

PUBLICATION EXCLUSIVE: ASCRS Research Council aims to mirror success of DRCR.net

March 22, 2017
The Diabetic Retinopathy Clinical Research Network is a collaboration among the National Eye Institute, the National Institute of Diabetes and…

Phase 1/2 trial of gene therapy treatment for X-linked retinitis pigmentosa begins

March 22, 2017
A phase 1/2 clinical trial of a gene therapy treatment for X-linked retinitis pigmentosa has begun enrolling and dosing subjects, NightstaRx…

Publication Exclusive

PUBLICATION EXCLUSIVE: Woman presents with cloudy declining vision and flashes

March 20, 2017
A 56-year-old Caucasian woman presented with painless, slowly decreasing “murky” vision in the left eye over a period of 3 weeks, along…

More Headlines »
Advertisement
Advertisement